- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04693949
Effect of Nano-structured Alumina Coating on the Bond Strength of Zirconia Resin-bonded Fixed Dental Prostheses
The purpose of this study is to evaluate the clinical outcome of resin-bonded fixed dental prostheses (RBFDPs) pretreated with nanostructured alumina coating (NAC).
The study adopts a prospective, randomized, controlled, double-blind design contrasting the use of NAC to air-borne particle abrasion (APA) (control) as a surface pretreatment method of zirconia RBFDPs used for replacing missing central or lateral incisors. The primary outcome evaluated is the retention/survival of the zirconia RBFDPs pretreated with APA and NAC.
Study Overview
Status
Intervention / Treatment
Detailed Description
Zirconia resin-bonded fixed dental prostheses (RBFDPs) have been regarded as a promising minimally invasive alternative for the replacement of missing central and lateral incisors, offering several advantages to orthodontic space closure or tooth replacement with implant-supported restorations. Debonding of the zirconia RBFDPs represents the main technical complication since clinically established airborne particle abrasion (APA) of an inert zirconia surface does not always provide sufficient resin-bond strength. Further, APA can also impair the mechanical properties of zirconia restoration affecting its long-term success. Nano-structured alumina coating (NAC) presents an alternative non-invasive zirconia surface pretreatment. The aim of this randomized controlled clinical trial is to study the effect of NAC coated bonding surface of zirconia RBFDPs affecting its debonding and clinical survival rate.
The study adopts a prospective, randomized, controlled, double-blind design contrasting the use of NAC to air-borne particle abrasion (APA) as a surface pretreatment method of zirconia RBFDPs. Healthy patients in need of a missing central or lateral incisor replacement are screened and rated to be eligible by two calibrated dentists. RBFDPs are randomly allocated into two groups and inserted by the same operator. The first group, where the bonding surface is pretreated with APA serves a control group. In the second group the restorations are pretreated with NAC. The participants and the operator are blinded to the group assignment in a double-blinded trial design. The primary outcome evaluated is the retention/survival of the RBFDP. Non-parametric tests and Kaplan-Meyer analysis will be used to determine differences between both study groups.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tine Malgaj, DMD
- Phone Number: +386 31 410140
- Email: tine.malgaj@mf.uni-lj.si
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- Recruiting
- Medical Faculty - University of Ljubljana Ljubljana
-
Contact:
- Tine Malgaj, DMD
- Phone Number: +386 31 410140
- Email: tine.malgaj@mf.uni-lj.si
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Patients with missing central or lateral incisor
Exclusion Criteria:
- inadequate edentulous space for the pontic
- signs of bruxism
- abutment tooth with active periodontal or periapical disease
- inadequate enamel bonding surface of the abutment tooth
- inadequate interocclusal space for a retainer wing and a proximal connector
- pontic guidance
- physical or psychological disease likely to interfere with normal conduct of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: APA
Air-borne particle abrasion of zirconia RBFDPs prior to bonding
|
Air-borne particle abrasion of zirconia RBFDPs prior to bonding
|
Experimental: NAC
Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
|
Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival rate of zirconia RBFDPs
Time Frame: From baseline through study completion, an average of 1 year
|
Survival rate is defined by debonding or restoration loss
|
From baseline through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Porcelain chipping
Time Frame: From baseline through study completion, an average of 1 year
|
Porcelain chipping
|
From baseline through study completion, an average of 1 year
|
Zirconia framework fracture
Time Frame: From baseline through study completion, an average of 1 year
|
Zirconia framework fracture
|
From baseline through study completion, an average of 1 year
|
Gingivitis
Time Frame: From baseline through study completion, an average of 1 year
|
Visual and tactile inspection of gingiva
|
From baseline through study completion, an average of 1 year
|
Parodontitis
Time Frame: From baseline through study completion, an average of 1 year
|
Gingival sulcus depth measurement
|
From baseline through study completion, an average of 1 year
|
Marginal leakage
Time Frame: From baseline through study completion, an average of 1 year
|
Discoloration of a restoration margin
|
From baseline through study completion, an average of 1 year
|
Secondary caries
Time Frame: From baseline through study completion, an average of 1 year
|
Caries between the tooth and restoration margin
|
From baseline through study completion, an average of 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Adhesion of RBFDPs
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Children
-
Duke UniversityBoston Children's Hospital; Agency for Healthcare Research and Quality (AHRQ)Enrolling by invitationChildren, Only | Children and Youth With Special Healthcare NeedsUnited States
-
Elizabeth Glaser Pediatric AIDS FoundationUnited States Agency for International Development (USAID); Biomedical Research... and other collaboratorsTerminatedOrphans, Children, Adolescents | Vulnerable Children, Adolescents | Community-basedZimbabwe
-
National Institute of Mental Health (NIMH)RecruitingHealthy Children | Children With Neurodevelopmental Disorders | Children With Neuropsychiatric Disorders | Children With Behavioral SyndromesUnited States
-
Georgetown UniversityPenn State UniversityCompleted
-
Sheffield Children's NHS Foundation TrustUniversity of Sheffield; Sheffield Hallam UniversityCompletedChildrenUnited Kingdom
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedChildrenUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompleted
-
Burke Medical Research InstituteNot yet recruiting
Clinical Trials on APA
-
GERCOR - Multidisciplinary Oncology Cooperative...Active, not recruitingMetastatic Pancreatic Cancer | Unresectable Locally Advanced CancerFrance
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineRecruitingAnxiety | Hematological Malignancies | Relaxation | Adapted Physical ActivityFrance
-
Centre Hospitalier Universitaire de BesanconGERCOR - Multidisciplinary Oncology Cooperative GroupRecruiting
-
Centre Henri BecquerelUnknown
-
University Hospital, LimogesTerminated
-
Chang Gung UniversityCompleted
-
Johns Hopkins UniversityCompletedAromatase Inhibitor | Musculoskeletal Symptoms | Postmenopausal Breast Cancer SurvivorsUnited States
-
Centre Hospitalier Universitaire de NiceNot yet recruitingNeurocognitive DisordersFrance
-
Johns Hopkins UniversityTerminatedAcupressure | Cancer-related PainUnited States
-
VA Office of Research and DevelopmentUniversity of Maryland, Baltimore County; MedStar National Rehabilitation Network and other collaboratorsCompleted